Bio-Rad Laboratories BIO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's additional paid-in capital?
- Bio-Rad Laboratories (BIO) reported additional paid-in capital of $490.5M in Q1 2026.
- How has Bio-Rad Laboratories's additional paid-in capital changed year-over-year?
- Bio-Rad Laboratories's additional paid-in capital increased by 3.1% year-over-year, from $475.7M to $490.5M.
- What is the long-term trend for Bio-Rad Laboratories's additional paid-in capital?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's additional paid-in capital has grown at a 2.1% compound annual growth rate (CAGR), from $429.38M to $476M.
- What does additional paid-in capital mean?
- The total amount of money shareholders paid for their shares above the nominal par value.
- How do you interpret additional paid-in capital?
- Increases typically reflect equity financing activities or the accounting impact of employee stock-based compensation.
- How does additional paid-in capital compare across companies?
- Standard equity component for all publicly traded companies.